Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

19.95
+0.06000.30%
Post-market: 19.950.00000.00%19:30 EDT
Volume:2.56M
Turnover:51.35M
Market Cap:3.44B
PE:9.09
High:20.24
Open:20.01
Low:19.88
Close:19.89
52wk High:30.96
52wk Low:19.59
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.84
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:2.63
PE(LYR):8.67

Loading ...

Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating

MT Newswires Live
·
Aug 10

Acadia Pharmaceuticals CFO Mark C. Schneyer Disposes of 25,141 Common Shares Worth $730,047.52

Reuters
·
Aug 08

ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus

Simply Wall St.
·
Aug 06

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

Reuters
·
Aug 06

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

Reuters
·
Aug 06

Acadia Pharmaceuticals is Maintained at Perform by Oppenheimer

Dow Jones
·
Aug 06

ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says

MT Newswires Live
·
Aug 06

Acadia Pharmaceuticals, Inc. : Oppenheimer Raises Target Price to $25 from $23

THOMSON REUTERS
·
Aug 05

RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating

MT Newswires Live
·
Aug 05

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

Reuters
·
Aug 05

Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Aug 05

Strong Partner Sales Propel Neuren Pharmaceuticals to Top of Australia Benchmark

Reuters
·
Aug 05

Acadia Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Earnings Flash (ACAD) ACADIA Pharmaceuticals Posts Q2 EPS $0.18, vs. FactSet Est of $0.06

MT Newswires Live
·
Aug 05

Acadia Q2 FY26 Net Income Rises 18% to $32 Million; Net Sales Climb 16% to $308 Million

Reuters
·
Aug 05

Acadia Pharmaceuticals Q2 Revenue Rises on Daybue STIX Demand, Lifts 2026 Outlook

Reuters
·
Aug 05

ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate

Benzinga Earnings
·
Aug 05

Acadia Pharmaceuticals Q2 EPS USD 0.18

Reuters
·
Aug 05

Acadia Pharmaceuticals Outlook FY Revenue USD 1,240-1,300 Million

THOMSON REUTERS
·
Aug 05

Acadia Pharmaceuticals: Lowers Fy2026 R&D Expense Guidance to $355-$380 Mln

THOMSON REUTERS
·
Aug 05